Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (571-580 of 962) with videos related to

Pageof 97
Sort By:
Thrombosis and Haemostasis|February 5, 2016
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implicationsGary E Raskob, Alex C Spyropoulos, Julie Zrubek, et al.
Journal of the American College of Cardiology|October 27, 2022
Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary SyndromesGorav Batra, Johan Lindbäck, Richard C Becker, et al.
JACC. Cardiovascular Interventions|February 24, 2015
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])Harvey D White, Deepak L Bhatt, C Michael Gibson, et al.
American Heart Journal|March 20, 2012
Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT)Harmony R Reynolds, Sandra A Forman, Jacqueline E Tamis-Holland, et al.
American Heart Journal|December 5, 2016
Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapyAnna Grodzinsky, Suzanne V Arnold, Tracy Y Wang, et al.
European Heart Journal|April 1, 2014
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trialSteen Husted, Stefan K James, Richard G Bach, et al.
JACC. Cardiovascular Interventions|April 7, 2021
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI TrialBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
The Lancet. Neurology|October 12, 2007
A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effectsPhilippa C Lavallée, Elena Meseguer, Halim Abboud, et al.
The American Journal of Cardiology|November 7, 2015
Factors Associated With Infarct-Related Artery Patency Before Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the FAST-MI 2010 Registry)Clotilde Bailleul, Etienne Puymirat, Nadia Aissaoui, et al.
European Journal of Preventive Cardiology|December 26, 2025
Prediction of inclisiran efficacy in patients with established atherosclerotic cardiovascular disease: the SIRIUS In-Silico modelling of cardiovascular outcomesDenis Angoulvant, Emmanuel Peyronnet, Bertrand Cariou, et al.
Pageof 97

Showing results (571-580 of 962) with videos related to

Sort By:
Pageof 97
Thrombosis and Haemostasis|February 5, 2016
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implicationsGary E Raskob, Alex C Spyropoulos, Julie Zrubek, et al.
Journal of the American College of Cardiology|October 27, 2022
Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary SyndromesGorav Batra, Johan Lindbäck, Richard C Becker, et al.
JACC. Cardiovascular Interventions|February 24, 2015
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])Harvey D White, Deepak L Bhatt, C Michael Gibson, et al.
American Heart Journal|March 20, 2012
Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT)Harmony R Reynolds, Sandra A Forman, Jacqueline E Tamis-Holland, et al.
American Heart Journal|December 5, 2016
Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapyAnna Grodzinsky, Suzanne V Arnold, Tracy Y Wang, et al.
European Heart Journal|April 1, 2014
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trialSteen Husted, Stefan K James, Richard G Bach, et al.
JACC. Cardiovascular Interventions|April 7, 2021
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI TrialBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
The Lancet. Neurology|October 12, 2007
A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effectsPhilippa C Lavallée, Elena Meseguer, Halim Abboud, et al.
The American Journal of Cardiology|November 7, 2015
Factors Associated With Infarct-Related Artery Patency Before Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the FAST-MI 2010 Registry)Clotilde Bailleul, Etienne Puymirat, Nadia Aissaoui, et al.
European Journal of Preventive Cardiology|December 26, 2025
Prediction of inclisiran efficacy in patients with established atherosclerotic cardiovascular disease: the SIRIUS In-Silico modelling of cardiovascular outcomesDenis Angoulvant, Emmanuel Peyronnet, Bertrand Cariou, et al.
Pageof 97